GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Shiller PE Ratio

SLN (Silence Therapeutics) Shiller PE Ratio : (As of Mar. 28, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Silence Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Silence Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Shiller PE Ratio Chart

Silence Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Silence Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Silence Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Silence Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Shiller PE Ratio falls into.


;
;

Silence Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Silence Therapeutics's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Silence Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.307/135.1000*135.1000
=0.307

Current CPI (Dec. 2024) = 135.1000.

Silence Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200912 -4.410 88.900 -6.702
201006 -3.780 90.200 -5.662
201012 -1.020 91.700 -1.503
201106 -1.455 93.500 -2.102
201112 -0.345 95.000 -0.491
201206 -6.150 95.600 -8.691
201212 2.145 97.300 2.978
201306 -0.252 98.000 -0.347
201312 -0.348 99.200 -0.474
201406 -0.345 99.800 -0.467
201412 -0.315 99.900 -0.426
201506 -0.213 100.100 -0.287
201512 -0.099 100.400 -0.133
201606 -0.204 101.000 -0.273
201612 -0.159 102.200 -0.210
201706 -0.237 103.500 -0.309
201712 0.168 105.000 0.216
201806 -0.372 105.900 -0.475
201812 -0.414 107.100 -0.522
201906 -0.345 107.900 -0.432
201912 -0.345 108.500 -0.430
202006 -0.411 108.800 -0.510
202009 -0.425 109.200 -0.526
202012 -0.674 109.400 -0.832
202103 -0.400 109.700 -0.493
202106 -0.544 111.400 -0.660
202109 -0.447 112.400 -0.537
202112 -0.432 114.700 -0.509
202203 -0.339 116.500 -0.393
202206 -0.484 120.500 -0.543
202209 -0.241 122.300 -0.266
202212 -0.595 125.300 -0.642
202303 -0.353 126.800 -0.376
202306 -0.363 129.400 -0.379
202309 -0.271 130.100 -0.281
202312 -0.504 130.500 -0.522
202403 -0.053 131.600 -0.054
202406 -0.421 133.000 -0.428
202409 -0.767 133.500 -0.776
202412 0.307 135.100 0.307

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Silence Therapeutics  (NAS:SLN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Silence Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Silence Therapeutics Business Description

Traded in Other Exchanges
Address
72 Hammersmith Road, London, GBR, W14 8TH
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.